Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease

By Salam Amar M   Al Suwaidi Jassim  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1645-1658

Informa Healthcare

Access to resources Recommend Favorite

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

By Murphy J.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 2, 2003-01 ,pp. : 101-112

Adis International

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review

By Anne Ganeshkumar   Gruberg Luis  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 335-348

Informa Healthcare

Access to resources Recommend Favorite

Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease?

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 10, 2003-10 ,pp. : 1709-1712

Informa Healthcare

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa receptor antagonists

By Casserly I.P.   Moliterno D.J.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 419-433

Informa Healthcare

Access to resources Recommend Favorite